Leveraged Bets: A Reckoning

These aren’t tools for the patient farmer, building wealth season by season. They’re for those who seek a swift harvest, a gamble against the unpredictable weather of the market. SSO, doubling the movements of the S&P 500, spreads the risk, a wider net cast across the economic landscape. SOXL, however, concentrates all hope on the fortunes of the semiconductor industry, a sector both vital and volatile, a narrow path through a tangled wood. To understand which might suit a man’s hand, one must look beyond the promised returns, and consider the nature of the soil itself.

VXUS/VYMI: The Global Tilt & The Coming Carnage

For months now, the whispers have been growing louder. Non-U.S. stocks, those forgotten relics of a pre-American empire, are actually… outperforming. Yes, you read that correctly. The Vanguard Total International Stock ETF (VXUS +0.50%), holding over 8,000 global companies, is up a respectable 25% in the last year. Matching the Nasdaq, even. It’s a subtle shift, a hairline fracture in the bedrock of our financial hubris, but trust me, it’s there. And it’s growing.

Xenon: A Risky Play, But Oh, the Numbers

The filing shows Driehaus increased its stake in Xenon during the fourth quarter. A tidy little addition to their portfolio. It’s now 1.4% of their 13F reportable assets. Which, let’s be honest, is a commitment. Like, “I’m seeing this through, even if it involves late-night stress-eating and questionable life choices” kind of commitment. The total position value bumped up to $36.03 million. Numbers. They’re mesmerizing, aren’t they? Especially when they represent someone else’s money.

Ephemeral Fortunes: Korea, Chips, and the Illusion of Control

The principal casualties, naturally, were the titans of memory. Samsung Electronics and SK Hynix, those vast, inscrutable organizations, saw their valuations diminish with an almost poetic inevitability. Together, they constitute a rather alarming proportion – over thirty-three percent – of the entire KOSPI. A concentration of risk that one might describe, with a touch of weariness, as ‘suboptimal.’ It speaks volumes, doesn’t it, about the fragile foundations upon which these modern fortunes are built?

Eos Energy: A Current in the Grid

The papers showed a transaction of around $110.72 million, calculated on the quarter’s average price. Driehaus now holds 14.27 million shares, a position grown by $88.76 million since last quarter. These aren’t just figures on a screen; they represent a confidence, a wager on the possibility of a different future. It’s a bet on holding onto what’s given freely, and releasing it when needed.

TSMC: Chips, Anxiety, and a Maybe-Okay Investment

Everyone’s talking about the Magnificent Seven, but honestly, I find their hype exhausting. They’re the popular kids in high school, constantly demanding attention. TSMC, on the other hand, is the kid who builds the robots for the popular kids. They don’t need the validation. They just…make the chips. And right now, they’re making a lot of money doing it. The stock is up almost 11% to start the year, and 107% over the last 12 months. A market cap of over $1.8 trillion? It feels… precarious. Like a Jenga tower built on a foundation of optimism.

Marvell: A Chip and a Promise

The current projections suggest these Alchemists will collectively spend some $650 billion this year on the infrastructure. That’s a figure that makes even the most seasoned accountant reach for the smelling salts. Last year it was ‘only’ $410 billion. Not that ‘only’ applies to sums that could fund a small kingdom. OpenAI and Anthropic are also getting in on the act, as are newer players like CoreWeave and Nebius, all desperate to build more and more ‘compute capacity’ – a phrase that sounds suspiciously like hoarding magical energy. It’s a bit like a dragon collecting gold, really. Except the gold is silicon, and the dragon is a data center.

Praxis Precision: A Budding Neuroscience Venture

The filing with the Securities and Exchange Commission reveals an increase in Driehaus’s holdings, a deliberate weighting of their portfolio towards this particular venture. The transaction, valued at approximately $80.54 million based on the closing prices of December 31st, 2025, swelled the total PRAX stake by a considerable $248.48 million, a testament not merely to the purchase itself, but to the rising tide that carries such investments.

Syndax Pharmaceuticals: A Curious Case of Revenue

The filing with the Securities and Exchange Commission revealed that Sphera wasn’t merely dipping a toe in the water; they were building a respectable sandcastle. The purchase brought their total holdings to seven-hundred and sixty-two-thousand, five-hundred and sixty-three shares. The estimated value of the acquired shares was six-and-a-half million dollars. A figure inflated, no doubt, by the boundless optimism of the market. It’s a game of appearances, you see. A carefully constructed illusion of prosperity.